The Clinical Usefulness of 18F-FDG PET/CT in Patients with Systemic Autoimmune Disease

Nuclear Medicine and Molecular Imaging

Volumn 45, Issue 3, 2011, Pages 177-184

  Oh, Jong Ryool ^a   Song, Ho Chun ^a   Kang, Sae Ryung ^a   Yoo, Su Woong ^a   Kim, Jahae ^a   Chong, Ari ^a   Min, Jung Joon ^a   Bom, Hee Seung ^a   Lee, Shin Seok ^b   Park, Yong Wook ^b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Autoimmune disease; Neoplasms; PET CT; Reactive lymphoid hyperplasia; Tuberculosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; BIOACCUMULATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE DISPLAY; INCIDENTAL FINDING; INTERMETHOD COMPARISON; LYMPHADENOPATHY; MALE; NEOPLASM; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SYSTEMIC DISEASE; TUBERCULOSIS;

EID: 84863273153     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-011-0094-8     Document Type: Article

References (33)

1. Ramos-Casals M, Brito-Zeron P, Lopez-Soto A, Font J. Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. Autoimmun Rev. 2004; 3: 376-82.
2. Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev. 2010; 9: 195-9.
3. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001; 85: 473-83.
4. Sela O, Shoenfeld Y. Cancer in autoimmune diseases. Semin Arthritis Rheum. 1988; 18: 77-87.
5. Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases. Expert Opin Investig Drugs. 2010; 19: 195-213.
6. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med. 2009; 39: 36-51.
7. Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med. 2010; 51: 1937-49.
8. Chung HH, Nam BH, Kim JW, Kang KW, Park NH, Song YS, et al. Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging. 2010; 37: 1467-73.
9. Kumar TS, Aggarwal A. Approach to a patient with connective tissue disease. Indian J Pediatr. 2010; 77: 1157-64.
10. Beckers C, Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med. 2004; 45: 956-64.
11. Choe JY, Chung DS, Park SH, Kwon HH, Kim SK. Clinical significance of (1)F-fluoro-dexoxyglucose positron emission tomography in patients with adult-onset Still's disease: report of two cases and review of literatures. Rheumatol Int. 2010; 30: 1673-6.
12. dos Anjos DA, do Vale GF, Campos Cde M, do Prado LF, Sobrinho AB, da Cunha AL et al. Extra-articular inflammatory sites detected by F-18 FDG PET/CT in a patient with rheumatoid arthritis. Clin Nucl Med. 2010; 35: 540-1.
13. Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS, Dijkmans BA, et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med. 2011; 52: 77-80.
14. Funauchi M, Ikoma S, Kishimoto K, Shimazu H, Nozaki Y, Sugiyama M, et al. A case of adult onset Still's disease showing marked accumulation in the liver and spleen, on positron emission tomography-CT images. Rheumatol Int. 2008; 28: 1061-4.
15. Jadvar H, Bonyadlou S, Iagaru A, Colletti PM. FDG PET-CT demonstration of Sjogren's sialoadenitis. Clin Nucl Med. 2005; 30: 698-9.
16. Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med. 2009; 23: 783-91.
17. Nishiyama Y, Yamamoto Y, Dobashi H, Kameda T. Clinical value of 18F-fluorodeoxyglucose positron emission tomography in patients with connective tissue disease. Jpn J Radiol. 2010; 28: 405-13.
18. Nowak M, Carrasquillo JA, Yarboro CH, Bacharach SL, Whatley M, Valencia X, et al. A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus. Arthritis Rheum. 2004; 50: 1233-8.
19. Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009; 125: 398-405.
20. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med. 2008; 264: 514-27.
21. Soderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer. 2006; 42: 3028-33.
22. Volkers N. Do autoimmune diseases raise the risk of cancer? J Natl Cancer Inst. 1999; 91: 1992-3.
23. Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2009; 20: 1001-10.
24. Moulin-Romsee G, Hindie E, Cuenca X, Brice P, Decaudin D, Benamor M, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010; 37: 1095-105.
25. Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 2010; 30: 269-91.
26. Pelosi E, Penna D, Douroukas A, Bello M, Amati A, Arena V et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging. 2010. Dec 9. [Epub ahead of print].
27. Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau A, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging. 2009; 36: 1813-21.
28. Zampieri S, Ghirardello A, Iaccarino L, Briani C, Sarzi-Puttini P, Atzeni F, et al. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006; 39: 191-6.
29. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005; 38: 473-85.
30. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007; 56: 1754-64.
31. Patkar NM, Teng GG, Curtis JR, Saag KG. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol. 2008; 20: 320-6.
32. Sathekge M, Maes A, Kgomo M, Pottel H, Stolz A, van De Wiele C. FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging. Q J Nucl Med Mol Imaging. 2010; 54: 698-703.
33. Deol P, Vohra R, Saini AK, Singh A, Chandra H, Chopra P, et al. Role of Mycobacterium tuberculosis Ser/Thr kinase PknF: implications in glucose transport and cell division. J Bacteriol. 2005; 187: 3415-20.